TY - JOUR
T1 - Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
AU - Maenza, Janine R.
AU - Keruly, Jeanne C.
AU - Moore, Richard D.
AU - Chaisson, Richard E.
AU - Merz, William G.
AU - Gallant, Joel E.
PY - 1996
Y1 - 1996
N2 - In a case-control study to identify risk factors for fluconazole- resistant oroesophageal candidiasis in human immunodeficiency virus-infected patients, 25 patients with clinical and in vitro fluconazole-resistant candidiasis were paired with controls who had treatment-responsive candidiasis and who had been observed for similar time periods. After their first episode of candidiasis, patients who later developed fluconazole resistance had more treated episodes than did matched controls (cases, 3.1; controls, 1.8; P = .004), lower median CD4 cell counts (11/mm3 vs. 71/mm3; P = .004), and greater median durations of all antifungal therapy (419 vs. 118 days; P < .001) and of systemic azole therapy (272 vs. 14 days; P < .001). When paired with a second set of controls matched by CD4 cell count as well as first diagnosis of candidiasis, cases continued to show greater median exposure to azoles (272 vs. 88 days; P = .005). These data indicate that advanced immunosuppression and exposure to oral azoles are risk factors for the development of fluconazole resistance.
AB - In a case-control study to identify risk factors for fluconazole- resistant oroesophageal candidiasis in human immunodeficiency virus-infected patients, 25 patients with clinical and in vitro fluconazole-resistant candidiasis were paired with controls who had treatment-responsive candidiasis and who had been observed for similar time periods. After their first episode of candidiasis, patients who later developed fluconazole resistance had more treated episodes than did matched controls (cases, 3.1; controls, 1.8; P = .004), lower median CD4 cell counts (11/mm3 vs. 71/mm3; P = .004), and greater median durations of all antifungal therapy (419 vs. 118 days; P < .001) and of systemic azole therapy (272 vs. 14 days; P < .001). When paired with a second set of controls matched by CD4 cell count as well as first diagnosis of candidiasis, cases continued to show greater median exposure to azoles (272 vs. 88 days; P = .005). These data indicate that advanced immunosuppression and exposure to oral azoles are risk factors for the development of fluconazole resistance.
UR - http://www.scopus.com/inward/record.url?scp=0030042222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030042222&partnerID=8YFLogxK
U2 - 10.1093/infdis/173.1.219
DO - 10.1093/infdis/173.1.219
M3 - Article
C2 - 8537662
AN - SCOPUS:0030042222
SN - 0022-1899
VL - 173
SP - 219
EP - 225
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -